Ventrus Announces Improved, FDA-Recommended Endpoints Proposed for Phase III Hemorrhoid Study

Ventrus BioSciences, Inc. VTUS has filed a revised protocol with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment with new, more robust definitions for efficacy endpoints that were recommended by the FDA in a recent meeting with the company for the first pivotal study of the company's iferanserin (VEN 309) ointment, the first prescription product candidate for the treatment of hemorrhoids. Ventrus also announced that it will host a conference call on Monday, March 21 at 8:30 AM ET to discuss the proposed revised endpoints.